Literature DB >> 17958987

Evaluation of the Arkansas method of urine testing for isoniazid in South Africa.

Y Hanifa1, K Mngadi, J Lewis, K Fielding, G Churchyard, A D Grant.   

Abstract

SETTING: A South African hospital serving gold mine employees.
OBJECTIVE: To determine the sensitivity and specificity of the Arkansas method for detecting isoniazid (INH) metabolites among South African adults and to examine the effect of smoking status on positive results.
DESIGN: Urine specimens were collected from in-patients taking INH as part of tuberculosis treatment at 6, 12 and 24 h after a directly observed 300 mg oral dose. As a control group, a single urine specimen was collected from surgical in-patients not taking INH. Specimens were tested for INH using a commercially available dipstick.
RESULTS: A total of 153 patients on INH and 60 controls were recruited. The sensitivity of the test was 93.3% (95%CI 88.1-96.8) at 6 h post INH, 93.4% (95%CI 88.2-96.8) at 12 h and 77% (95%CI 69.1-83.7) at 24 h. The specificity of the test was 98.3% (95%CI 91.1->99.9). There was no association between smoking status and colour change of positive results.
CONCLUSIONS: This test is a useful method of monitoring adherence to TB treatment or preventive therapy among South Africans. However, it is less than 100% sensitive, especially with increasing time post dose, which should be taken into consideration when interpreting results for individual patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17958987

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  8 in total

1.  Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.

Authors:  Salome Charalambous; Alison D Grant; Craig Innes; Christopher J Hoffmann; Rob Dowdeswell; Jan Pienaar; Katherine L Fielding; Gavin J Churchyard
Journal:  AIDS       Date:  2010-11       Impact factor: 4.177

2.  The reliability and practicality of the Arkansas method assay of isoniazid adherence.

Authors:  Katharine E Schmitz; Melbourne F Hovell; Charlene A Wong; Norma J Kelley; Donata Nilsen; Elaine J Blumberg; Linda L Hill; Carol L Sipan; Bo Kolody; Dale A Chatfield
Journal:  Clin Nurs Res       Date:  2010-05       Impact factor: 2.075

3.  Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.

Authors:  V Amlabu; C Mulligan; N Jele; A Evans; D Gray; H J Zar; H McIlleron; P Smith
Journal:  Int J Tuberc Lung Dis       Date:  2014-05       Impact factor: 2.373

4.  Point-of-care Arkansas method for measuring adherence to treatment with isoniazid.

Authors:  Renata L Guerra; Marcus B Conde; Anne Efron; Carla Loredo; Gisele Bastos; Richard E Chaisson; Jonathan E Golub
Journal:  Respir Med       Date:  2010-03-03       Impact factor: 3.415

5.  Point-of-care urine tests for smoking status and isoniazid treatment monitoring in adult patients.

Authors:  Ioana Nicolau; Lulu Tian; Dick Menzies; Gaston Ostiguy; Madhukar Pai
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

6.  Adherence to isoniazid preventive therapy among child contacts in Rwanda: A mixed-methods study.

Authors:  Francine Mwayuma Birungi; Stephen Michael Graham; Jeannine Uwimana; Angèle Musabimana; Brian van Wyk
Journal:  PLoS One       Date:  2019-02-11       Impact factor: 3.240

7.  Urine Biomarker Assessment of Infant Adherence to Isoniazid Prophylaxis.

Authors:  Sylvia M LaCourse; Daniel Leon; Nuttada Panpradist; Barbra A Richardson; Elizabeth Maleche-Obimbo; Jerphason Mecha; Daniel Matemo; Jaclyn N Escudero; John Kinuthia; Barry Lutz; Grace John-Stewart
Journal:  Pediatr Infect Dis J       Date:  2021-01       Impact factor: 2.129

8.  Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic.

Authors:  Claudia C Dobler; Guy B Marks
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.